New expert recommendations aim to improve detection and care of lung disease in people with rheumatoid arthritis

A new international expert consensus statement published in The Lancet Respiratory Medicine(Opens in a new window) provides important guidance for doctors on how to identify, monitor and treat a serious lung complication that affects many people living with rheumatoid arthritis (RA).

RA is best known as a disease that causes joint pain and inflammation, but it can also affect the lungs. One of the most serious complications is rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a condition that causes scarring and inflammation in the lungs, making it harder to breathe and reducing quality of life.

“Rheumatoid arthritis doesn’t just affect the joints — it can also affect the lungs in ways that can significantly impact a person’s health and quality of life,” said Joshua Solomon, MD, lead author of the study and director of interstitial lung disease at National Jewish Health. “These recommendations provide practical guidance to help clinicians identify lung disease earlier, monitor patients more effectively and determine when treatment may be appropriate.”

Because there has been little agreement among medical experts about when patients should be screened for lung disease, how often they should be monitored and when treatment should begin, an international panel of specialists developed a set of consensus recommendations to help guide patient care.

The experts reviewed the available evidence and identified key risk factors that may increase the likelihood of developing RA-ILD. They also outlined recommendations for screening patients with RA who may be at higher risk, as well as approaches for monitoring disease progression and selecting treatment options.

The consensus statement emphasizes a team-based approach involving rheumatologists, pulmonologists and other specialists to help ensure patients receive comprehensive care. The recommendations are intended to help clinicians make informed decisions in situations where high-quality clinical trial data are limited. Researchers hope the guidance will lead to earlier diagnosis, more consistent care and improved outcomes for people living with RA-related lung disease.
 

This article is based on a press release from National Jewish Health.